Home › Compare › CATTF vs ABBV
CATTF yields 30303.03% · ABBV yields 3.06%● Live data
📍 CATTF pulled ahead of the other in Year 1
Combined, CATTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CATTF + ABBV for your $10,000?
CAT Strategic Metals Corporation engages in the acquisition and exploration of mineral properties in Canada. It primarily explores for uranium, gold, silver, and copper deposits. The company holds a 100% interest in the South Preston Uranium property covering approximately 29,395 hectares located in Saskatchewan, Canada; and the Gold Jackpot property comprising 64 unpatented lode claims that covers an area of 535 hectares located to the southeast of Jackpot, Nevada. It also holds interest in the Rimrock project that covers an area of 1,663 acres situated in Northwest of Elko, Nevada; and the Burntland mineral property covering approximately 1,200 hectares located in county of Restigouche, New Brunswick, Canada. The company was formerly known as Chimata Gold Corp. and changed its name to CAT Strategic Metals Corporation in February 2019. CAT Strategic Metals Corporation was incorporated in 2010 and is headquartered in Vancouver, Canada.
Full CATTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.